PLGA-loaded gold-nanoparticles precipitated with quercetin downregulate HDAC-Akt activities controlling proliferation and activate p53-ROS crosstalk to induce apoptosis in hepatocarcinoma cells

Molecules and Cells

Volumn 38, Issue 6, 2015, Pages 518-528

  Bishayee, Kausik ^a,b   Khuda Bukhsh, Anisur Rahman ^b   Huh, Sung Oh ^a  

^a Hallym University   (South Korea)

^b UNIVERSITY OF KALYANI   (India)

Author keywords

Apoptosis; Gold nanoparticles; Histone deacetylation; P53 ROS crosstalk; Quercetin

Indexed keywords

CASPASE 3; DNA; GOLD NANOPARTICLE; POLYGLACTIN; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; QUERCETIN; REACTIVE OXYGEN METABOLITE; GOLD; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; LACTIC ACID; METAL NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TP53 PROTEIN, HUMAN;

A375 CELL LINE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; EPIGENETICS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR INTERACTION; SUSTAINED DRUG RELEASE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

APOPTOSIS; CELL PROLIFERATION; DOWN-REGULATION; GOLD; HELA CELLS; HEP G2 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; LACTIC ACID; LIVER NEOPLASMS; METAL NANOPARTICLES; POLYGLYCOLIC ACID; QUERCETIN; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942885392     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.2339     Document Type: Article

References (38)

1. Ajazuddin, and Saraf S. (2010). Applications of novel drug delivery system for herbal formulations. Fitoterapia 81, 680-689.
2. Arvizo, R., Bhattacharya, R., and Mukherjee, P. (2010). Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv. 7, 753-763.
3. Bhadoriya, S.S., Mangal, A., Madoriya, N., and Dixit, P. (2011). Bioavailability and bioactivity enhancement of herbal drugs by “Nanotechnology”: a review. J. Curr.Pharmaceutical. Res. 8, 1-7
4. Bhattacharyya, S.S., Paul, S., De, A., Das, D., Samadder, A., Boujedaini, N., and Khuda-Bukhsh, A.R. (2011). Poly (lactide- co-glycolide) acid nanoencapsulation of a synthetic coumarin: Cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol. Appl. Pharmacol. 253, 270-282.
5. Bishayee, K., Ghosh, S., Mukherjee, A., Sadhukhan, R., Mondal, J., and Khuda-Bukhsh, A.R. (2013a). Quercetin induces cytochrome c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell Prolif. 46, 153-163.
6. Bishayee, K., Paul, A., Ghosh, S., Sikdar, S., Mukherjee, A., Biswas, R., Boujedaini, N., and Khuda-Bukhsh, A.R. (2013b). Condurango-glycoside-A fraction of Gonolobus condurango induces DNA damage associated senescence and apoptosis via ROS-dependent p53 signalling pathway in HeLa cells. Mol. Cell. Biochem. 382, 173-183.
7. Brannon-Peppas, L., and Blanchette, O.J. (2004). Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1659.
8. Daugaard, M., Nitsch, R., Razaghi, B., McDonald, L., Jarrar, A., Torrino, S., Castillo-Uuva, S., Rotblat, B., Li, L., Malliri, A., et al. (2013). Hace1 controls ROS generation of vertebrate Rac1- dependent NADPH oxidase complexes. Nat. Commun. 4, 2180
9. Duan, H., Heckman, C.A., and Boxer, L.M. (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol. 25, 1608-1619.
10. Falkenberg, K.J., and Johnstone, R.W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673-691.
11. Fulda, S., and Debatin, K.M. (2006). Extrinsic versus intrinsic apop- tosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
12. Ghosh, S., Bishayee, K., and Khuda-Bukhsh, A.R. (2014). graveoline isolated from ethanolic extract of ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. Phytother. Res. 28, 1153-1162
13. Hagelkruys, A., Sawicka, A., Rennmayr, M., and Seiser, C. (2011). The biology of HDAC in cancer: the nuclear and epigenetic components. Handb. Exp. Pharmacol. 206, 13-37.
14. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
15. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., and Elledge, S.J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75, 805-816.
16. Havsteen, B. (2002). The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 6, 67-202.
17. Huang, B.H., Laban, M., Leung, C.H., Lee, L., Lee, C.K., and Salto- Tellez, M. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12, 395-404.
18. Hurley, L.H. (2002). DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2, 188-200.
19. Jain, S., Hirst, D.G., and O’Sullivan, J.M. (2012). Gold nanoparticles as novel agents for cancer therapy. Br. J. Radiol. 85, 101-113.
20. Karbowski, M., and Youle, R.J. (2003). Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 10, 870-880.
21. Kim, M.J., Sun, Y., Yang, H., Kim, N.H., Jeon, S.H., and Huh, SO. (2012). Involvement of the cAMP response element binding protein, CREB, and cyclin D1 in LPA-induced proliferation of P19 embryonic carcinoma cells. Mol. Cells 34, 323-328.
22. Kumari, A., Yadav, S.K., and Yadav, S.C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloid. Surfaces. B. 75, 1-18.
23. Lee, H., and Odom, T.W. (2015). Controlling ligand density on nanoparticles as a means to enhance biological activity. Nanomedicine 10, 177-180.
24. Lemarie, A., and Grimm, S. (2011). Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer. Oncogene 300, 3985-4003.
25. Liu, S. (2012). Epigenetics advancing personalied nanomedicine in cancer therapy. Adv. Drug Deliv. Rev. 64, 1532-1543.
26. Loo, D.T. (2002). TUNEL Assay: An Overview of Techniques. In in situ detection of DNA damage: methods and protocol, Didenko, V.V. eds. (Spinger), pp. 313-323.
27. Maitland, M.L., and Schilsky, R.L. (2011). Clinical trials in the era of personalized oncology. CA Cancer J. Clin. 61, 365-381.
28. Marks, P.A., Richon, V.M., and Rifkind, R.A. (2000). Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216.
29. Mikhailov, V., Mikhailova, M., Pulkrabek, D.J., Dong, Z., Venkatachalam, M.A., and Saikumar, P. (2001). Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J. Biol. Chem. 276, 18361-18374.
30. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
31. Noh, J.H., Jung, K.H., Kim, J.K., Eun, J.W., Bae, H.J., and Xie, H.J. (2011). Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 6, e28103.
32. Puhl, A.C., Fagundes, M., dos Santos, K.C., Polikarpov, I., das Gragas, M.F., da Silva, F., Fernandes, J.B., Vieira, P.C., and Forim, M.R. (2011). Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin, by using factorial design. Int. J. Drug Deliv. 3, 683-698.
33. Shahabuddin, M.S., Gopal, M., and Raghavan, S.C. (2009). Intercalating cytotoxic, anti-tumour activity of 8-chloro and 4-morp96holinopyrimido [4′, 5′:4.5]thieno(2, 3-b)quinolone. J. Photochem. Photobiol. B. 94, 13-19.
34. Shahbazian, D., Sznol, J., and Kluger, H.M. (2012). Vertical pathway targeting in cancer therapy. Adv. Pharmacol. 65, 1-26.
35. Shobha Devi, C., Anil Kumar, D., Singh, S.S., Gabra, N., Deepika, N., Kumar, Y.P., and Satyanarayana, S. (2013). Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular “light switch” complexes. Eur. J. Med. Chem. 64, 410-421.
36. Talluri, S., and Dick, F.A. (2012). Regulation of transcription and chromatin structure by pRB. Cell Cycle 11, 3189-3198.
37. Vijayababu, M.R., Kanagaraj, P., Arunkumar, A., Ilangovan, R., Dharmarajan, A., and Arunakaran, J. (2006). Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Oncol. Res. 16, 67-74.
38. Yu, T., Robotham, J.L., and Yoon, Y. (2006). Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc. Natl. Acad. Sci. USA 103, 2653-2658.